Abstract
Dear editor,
The recent surge in popularity of the antidiabetic drug, Semaglutide, marketed under the names Wegovy (which has the highest concentration of the active drug), Rybelsus, and Ozempic, 1 for its notable efficacy in weight loss has raised pertinent considerations. Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that is administered once weekly. It is effective in reducing hemoglobin A1C levels and promoting weight loss in patients with type 2 diabetes. 2
Further studies demonstrated significant weight loss and improvements in cardiometabolic risk factors with evidence showing good toleration, although gastrointestinal adverse effects were common.2,3
While it is commendable to find a drug that offers promising results beyond its primary intended purpose, the skyrocketing demand in developed nations necessitates vigilance.
First and foremost, there is potential for off-label abuse. With societal pressure to attain perceived ideal body weights, it is conceivable that individuals may seek this medication outside of its primary indication, potentially exposing themselves to unforeseen risks. Long-term side effects, especially when taken by non-diabetics, are not yet well documented and require continued monitoring.
Furthermore, the surge in demand can invariably drive up costs. This inflation could inadvertently limit access for diabetic patients who genuinely require Semaglutide for glycemic control. Price escalation also means increased out-of-pocket expenses, further burdening the healthcare systems of many developed countries and by extension, stifling the likelihood of patronage and usage in low- and middle-income countries.
It is imperative that endocrinologists and by extension other medical professionals, policymakers, strategic stakeholders, and regulatory bodies remain vigilant. Best still, it is most convenient to note that Semaglutide is a prescription medication and should be used under the guidance of a physician. It is not intended for recreational or non-medical use. Ongoing research, public awareness campaigns about potential risks, a vetting system for usage, and a structured pricing mechanism are vital to ensuring that Semaglutide remains both accessible and safe.
